Lifecore Biomedical
LFCR
86 hedge funds and large institutions have $221M invested in Lifecore Biomedical in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 18 reducing their positions, and 17 closing their positions.
89% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 18
16% more capital invested
Capital invested by funds: $190M → $221M (+$30.6M)
0.38% more ownership
Funds ownership: 66.19% → 66.57% (+0.38%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
1% less funds holding
Funds holding: 87 → 86 (-1)
36% less call options, than puts
Call options by funds: $76K | Put options by funds: $118K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Grizzlyrock Capital
Chicago,
Illinois
|
+$4.95M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$2.56M |
| 3 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$920K |
| 4 |
State Street
Boston,
Massachusetts
|
+$900K |
| 5 |
BlackRock
New York
|
+$741K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2L
22NW LP
Seattle,
Washington
|
-$10.1M |
| 2 |
AWG
Alpha Wave Global
New York
|
-$509K |
| 3 |
Goldman Sachs
New York
|
-$321K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$254K |
| 5 |
Boston Partners
Boston,
Massachusetts
|
-$241K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$6.36K | -904 | Closed |
|
|
SAM
102
Smartleaf Asset Management
Boston,
Massachusetts
| – | -$4.25K | -620 | Closed |
|
|
FFO
103
Fortitude Family Office
Scottsdale,
Arizona
| – | -$1.87K | -265 | Closed |
|
LFCR Hedge Fund Activity: Q2 2025 in Review
86 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q2 2025, worth a combined $221M — up 16% from $190M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of LFCR and 16 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 34 added.
The largest buyer was Grizzlyrock Capital, opening a new position worth an estimated $4.95M. The largest seller was 22NW LP, cutting an estimated $10.1M.
- 86 institutional investors held Lifecore Biomedical (LFCR) as of Q2 2025, down from 87 in Q1 2025.
- Funds reported $221M of Lifecore Biomedical stock for Q2 2025, up 16% quarter-over-quarter.
- 16 funds opened new Lifecore Biomedical positions in Q2 2025 and 17 closed out, a net change of -1 holder.
- The largest Lifecore Biomedical buyer in Q2 2025 was Grizzlyrock Capital, an estimated $4.95M added.
- The largest Lifecore Biomedical seller in Q2 2025 was 22NW LP, an estimated $10.1M sold.
Based on aggregated 13F filings for Q2 2025.